Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

Similar documents
Adjusting Insulin Doses

Insulin Prior Authorization with optional Quantity Limit Program Summary

Background: Brief review of epidemiology, diagnosis, classification and pathophysiology of diabetes mellistus.

Mixed Insulins Pick Me

Insulin Regimens: Hitting Glycemia Targets

Inpatient Glycemic Management:

Diabetes Mellitus in the Pediatric Patient

Diabetes in Pregnancy

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Type 2 Diabetes Mellitus Insulin Therapy 2012

associated with serious complications, but reduce occurrences with preventive measures

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

AACN PCCN Review. Endocrine

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI

Comprehensive Diabetes Treatment

Diabetic Emergencies DKA, HHS, Hypoglycemia. Disclosure. Learning Objectives

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17

New Therapies for Diabetes Management: Hope or Headache?

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Converting lantus to humalog 75 25

Learning Objectives. Perioperative SWEET Success

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Leslie K Scott PhD, PNP-BC, CDE University of Kentucky

MANAGEMENT OF TYPE 1 DIABETES MELLITUS

8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

Type 1 Diabetes-Pathophysiology, Diagnosis, and Long-Term Complications. Alejandro J de la Torre Pediatric Endocrinology 10/17/2014

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth

Lantus levemir conversion

10/9/2017 OBJECTIVES DIABETES REVIEW

INSULIN ALLERGY OBJECTIVES CASE OF DL

Type I Type II Insulin Resistance

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy

Lantus to levemir conversion

Nph insulin conversion to lantus

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Important Stuff. Basal Bolus What Adjustments? Pt weighs 80kg

Poll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.

Starting and Helping People with Type 2 Diabetes on Insulin

Technology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE

The ABCs of MDI: Gaining a working knowledge of Multiple Daily Injection insulin therapy. Today s Presenter

Premixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products

INSULIN 101: When, How and What

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products

4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Diabetes Head to Toe May 31, 2017

Insulin Initiation and Intensification. Disclosure. Objectives

DIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Module 5. Understanding Insulin Therapy

8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations

Insulin Basic facts. Patient Education Patient Care Services. What is insulin? What types of insulin are there? Basal Insulin

Initiating Injectable Therapy in Type 2 Diabetes

Case Study: Competitive exercise

Drug Effectiveness Review Project Summary Report Long acting Insulins

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

SCHOOL HEALTH PLAN: DIABETES

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

5/12/2011. Recognize the major types of diabetes: Type 2, Type 1A, Type 1B, MODY, LADA, Pancreatic diabetes, drug-induced DM

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

In-hospital management of diabetes

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Conversion from lantus to tresiba

ANNUAL MEETING 2 #FSHP2017

THE CURRENT APPROACH TO T1D IN CHILDREN

The York Diabetes Care Model

Individualizing Care for Patients with Type 2 Diabetes

Diana McNeill MD, FACP Professor of Medicine Duke University Medical Center. Disclosures

DIABETES MELLITUS. IAP UG Teaching slides

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Guide to Starting and Adjusting Insulin for Type 2 Diabetes*

INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.

Managing Diabetes when you are having a colonoscopy

CANDY Camp Application

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

Diabetes Related Disclosures

Insulin Management. By Susan Henry Diabetes Specialist Nurse

Insulin 10/11/17. Disclosures. Objectives. Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI)

Implementing Hospital Policies & Protocols

Update on Insulin-based Agents for T2D

Learning Objectives. Are you ready for more insulin formulations?

Application of the Diabetes Algorithm to a Patient

Basic Diabetes Mellitus Patient Education

Type 1 Diabetes Update Robin Goland, MD

Using Insulin in the Primary Care Setting: Interactive Cases


I. General Considerations

Advanced Diabetes Mellitus Education Information

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Transcription:

1.19.18 Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

DISCLOSURES 1. No financial incentives 2. Volunteer Positions 1. National Certification Board for Diabetes Educators, Chair, Examination Committee 2. American Diabetes Association: Safe at Schools, Advocacy, and Science/ Technology referee for Scientific Sessions, annual ADA meeting (2017-) 3. Diabetes Clinical Advisory Committee, Washington DC 2

Learning Objectives At the conclusion of this webinar, attendees will be able to: 1. Identify signs and symptoms of diabetes in the office setting 2. Describe the latest basal and bolus insulins, and apply insulins to construct insulin regimens 3. Classify and differentiate the different types of diabetes 3

Case Presentation Chief Complaint: 4 year old boy presents to your office with history of wetting the bed with increasing frequency over the past 2 weeks. History of the Present Illness: The child has been drinking more; however, it is summer time so the mother was not concerned. He goes to the bathroom on his own and has been at day camp, so she is unsure how much he is urinating during the day. He does, however, interrupt play to run into the bathroom. His appetite is very good, no fever. He did have a URI several weeks ago, but otherwise has been well Past Medical History: Frequent episodes of otitis media as an infant, but no major illnesses. He did have Varicella 6 months ago (breakthrough of Varivax vaccine). He is growing well and physically active. Medications: none 4

Case Presentation continued Immunizations: up to date Allergies: none Family History: type 1 diabetes in father (onset age 21), paternal aunt and uncle died from complications of type 1 diabetes in early 20 s ( aunt- diabulemia and uncle car accident, secondary to hypoglycemia). No history of type 2 diabetes, Plus history of low thyroid, no celiac disease or JRA. Social History: child lives with parents and 7 year old sibling. He currently is attending summer camp. Physical exam: VS: BP: 100/72, P=90, RR=28 To-98.7, weight: 18 kg, height= 105 cm 5

Case Presentation continued Skin: no rashes, mild dryness, no acanthosis nigricans HEENT: TM s negative, Pharynx: mild erythema, no exudates. Neck: palpable thyroid Lungs: Clear Cardiac: Regular Rhythm, no rubs, gallops or murmurs Abdomen: soft, +/-tenderness,? Rebound, no increased liver or spleen GU: normal, testes descended, no flank tenderness, no suprapubic tenderness Extremities: full range of motion, no leg weakness Neuro: normal mental status, bulk and tone. No spasticity 6

Differential Diagnostic Considerations 1. R/o family history of nocturnal enuresis 2. R/o UTI 3. R/o Psychosocial issues 1. New sibling 2. Divorce 3. Relocation 4. Death in the family 5. abuse 6. Any of the top 10 stressors 4. R/o Drinking too much before bedtime 5. R/o Neuropathic bladder (spinal cord abnormality etc.) 6. R/o new onset Diabetes Mellitus 7. R/o new onset Diabetes Insipidus 7

Office Laboratory Evaluation 1. Urinalysis: 4+ glucose/ moderate ketones, trace protein, negative nitrate, negative LE. Micro: negative, sg: 1030 2. Finger stick glucose (from office glucometer- if available): 300 Diagnostic considerations based on office lab results: 1. Hyperglycemia with ketosis- rule out type 1 diabetes mellitus 2. UTI ruled out 3. Family history significant: no history of nocturnal enuresis, positive family history of T1DM and thyroid disease 4. No evidence of new stressors in family 5. Normal neurological exam 6. No evidence of DI 8

Next steps 1. Leading Diagnosis based on presentation, physical exam, family history and office lab evaluation: new onset diabetes, most likely Type 1. 2. Child sent to CN ED for further evaluation: Laboratory tests Results Blood sugar (random) 375 Urine ketones moderate Na 132 Cl 3.0 BUN 18 Cr 0.9 ph 7.3 HCO3 15 9 Hb A1c 11%

Diagnostic Criteria: 1. Signs and symptoms of diabetes in association with a random blood sugar>/=200 mg/dl (laboratory value, NOT finger stick)- typical presentation for T1DM 2. Fasting blood sugar on 2 occasions>126 mg/dl 3. Oral glucose tolerance test : 2 hour post prandial blood sugar after consumption of 75 grams carbohydrate>/=200 mg/dl 4. Hb A1c >/= 6.5 % (3 month average blood sugar @ 140 mg/dl) TYPICAL ED CAVEATS THAT MAY BE MISTAKEN FOR NEW ONSET T1DM: 1. stress induced hyperglycemia 2. Steroid induced hyperglycemia 3. Medication induced hyperglycemia Diagnosis: New onset diabetes, most likely Type 1 based on criteria #s: 1 and 4 10

Management of Type 1 Diabetes: Think like a pancreas BASAL INSULINS 1. Glargine- 24 hour-flat profile 1. Lantus 2. Basaglar 3. Toujeo (3 times concentrated) 2. Detemir- (Levemir) (12-16 hours-flat profile 3. Degludec-(Tresiba) (48-72 hours-flat profile) 4. NPH- 8-10 hours- peak profile BOLUS INSULINS Rapid Acting 1. Lispro (humalog)-1.5-3 hours profile 2. Aspart (novolog)-1.5-3 hour profile 3. Glulisine (apidra)-1.5-3 hour profile Fast Acting 4. Regular Insulin: 2-4 hour profile Premixed Insulins 1. Novolog mix 70/30 (attenuated) novolog mixed with rapid acting) 2. Humalog mix 75/25 (attenuated humalog mixed with rapid acting 3. Humulin 70/30 (NPH/regular) 11

Insulin Action BOLUS Insulin REGULAR Insulin Action Onset 30 minutes Onset BOLUS Insulin Humalog (lispro) Novolog (aspart) Apidra (glulisine) Regular (Bolus) 30 minutes Insulin Overview Intermediate Basal Insulin NPH Humalog Novolog Apidra (Bolus) 5-30 minutes 24 hour basal Insulin Lantus/ Basaglar (glargine) Types of Insulin NPH (Basal) 24-42 hour Basal insulin Tresiba (Degludec) Very long acting Lantus (Basal) Levemir (Basal) 1-2 hours 1-2 hours 1-2 hours 24 hour basal insulin Toujeo (concentrated Glargine) 24 hour Basal insulin Levemir (Detemir) 5-10 minutes 1-2 hours 1-2 hours 1-2 hours 1-2 hours 1-2 hours Peak 2-3 hours 1-2 hours 6-8 hours none none none none Duration 4-6 hours 3-4 hours 10-12 hours 24 hours 42 hours 24 hours 12-18 hours Other Clear U-100 Vial None, but Peak Clear 2-3 hours Cloudy 1-2 hours Clear 6-8 hours Clear None slight in Clear larger U-100 U-100 U-100 U-100 or U-200 doses U-300 (1.5 Vial, pen Vial or pen Vial or pen Pen only ml) Duration only cartridge Keep open Keep for 1 4-6 hours pen 3-4 at hours 10-12 hours Good 20-24 for hours 56 days (8 450 units/pen month only 12-18 hours Pen only Keep pen wks) @ room room temp Do not mix Good for 42 1 month temp OR for 10 with other only at days insulins in room temp same OR in syringe refrig Give once a Other Can mix Clear Clear day Cloudy within With NPH only Open pens At room temp 2 hr window Open pens must be at room temp days (6 wks) refrigerated Clear Open pens Give @same Clear time Keep for must one Keep for one each day if month be only! at room month only! Do possible Do not mix temp with not mix with other other insulins insulins Never use in same a syringe Give once/day to in same syringe. removetresiba within 2 hour Give syringe. May once from a pen window day within need once or 1-2 Wait hour 3-4 window. days Never use a twice a syringe day to between dose changes remove Toujeo from the pen Clear U-100 Vial or pen Keep for 42 days (6 weeks only) Usually 2 injections/ day 12 hours apart Do not mix with other insulins in the same syringe. May need twice a day Open pens must be at room temp

Plasma Insulin Optimized Insulin Replacement Regimen: Mimicking Physiology With Basal and Prandial Insulin Normal Breakfast Lunch Dinner Prandial Basal 4:008:0012:0016:0020:0024:0028:0032:00 Time White JR Jr et al. Postgrad Med. 2003;113:30-36. 2011

Insulin calculations 1. Typical starting insulin dose: 0.6-1.0 unit/kg/day in child NOT in DKA 2. Typical initial regimen: modified basal/bolus therapy: 1. Basal insulin: Lantus/ Levemir/Basaglar : 40-50% of daily dose 2. Bolus insulin : Humalog/novolog/apidra: 50-60% of daily dose Total Daily Dose for our 4 year old: 18 kg x 0.85 units/kg=15.3 units Basal: 6 units hs or am (40% of Total daily dose) Bolus: 9 units for meals: Breakfast: 3 units Lunch: 3 units Dinner: 3 units How do you correct for higher blood sugars initially before moving to moving to more intensive insulin therapy? ADD a sliding scale until family returns for further education to learn Insulin/carb ratios and Correction factors. 14

Calculating initial sliding scales 1. Create a target blood sugar- where you wish the child to be! Our patient: goal blood sugar: 150 mg/dl (based on age) 2. Calculate a correction factor for a sliding scale 1800 (constant) divided by total daily dose= correction factor or the amount 1 unit of insulin will lower the blood sugar 1800 divided by 15 units (total daily dose)=120 mg/dl Therefore, 1 unit will lower our patient s blood sugar by 120 mg/dl based on his insulin requirements. 1. Calculation of sliding scale 1800 (constant) divided by total daily dose= correction factor or the amount 1 unit of insulin will lower the blood sugar 1800 divided by 15 units (total daily dose)=120 mg/dl Therefore, 1 unit will lower our patient s blood sugar by 120 mg/dl based on his insulin requirements. 15

Sliding scale calculation: Sliding scale calculations: Correction factor: 120 Target blood sugar: 150 mg/dl: For blood sugars: <150: 3 units rapid acting insulin 151-210: 3.5 units rapid acting insulin 211-270: 4.0 units rapid acting insulin 271-330: 4.5 units rapid acting insulin 331-390: 5.0 units rapid acting insulin or use the following algorithm: Actual Blood sugar-target (150) divided by Correction factor (120)= correction insulin added to base of 3 units 350-150 divided by 120= 1.66 units correction insulin Therefore, meal insulin would be 3 units for food + 1.5 (or 2 units-rounded)= 4.5 or 5 units Blood sugars are then followed for several weeks and return to class to learn to use Insulin/carbohydrate ratios with correction factors. 16

Diabetes not all Type 1 or Type 2: how to differentiate 1. T1 DM 2. T2 DM 3. Type 1.5 DM 4. Monogenic diabetes Rapid onset, polyuria, polydipsia, weight loss. Generally autoimmune in origin (HLA region). Positive GAD-65 antibodies. Risk of DKA, thin phenotype. Treated with insulin. Not all +GAD Gradual onset, obese phenotype with evidence of insulin resistance (acanthosis nigricans), possible weight loss, may present with ketones and DKA, no autoimmunity, family history, metabolic syndrome. Treated with Metformin/ and insulin if necessary Combination of type 1 and 2 with phenotype of T2 and autoimmunity of type 1 Includes neonatal diabetes- presents from birth to 12 months, MODY (maturity onset diabetes of youth) Etiology: genetic defect in insulin receptor 17

Diabetes- Not all Type 1 or Type 2- how to differentiate 5. Medication Induced Diabetes Etiology due to steroids, chemotherapy etc. Often requires insulin therapy 6. Cystic Fibrosis Related Diabetes (CFRD) Related to destruction of pancreatic cells (exocrine and endocrine) treated with insulin 7. Diabetes secondary to pancreatectomy Loss of beta cells treated with insulin pancreatectomy secondary to hyperinsulinemia 18

Technology and Diabetes 1. Insulin pump therapy 1. Metronic Minimed Hybrid Pancreas- 2. Tandem T-slim- touch screen 3. Omnipod- tubeless pump 2. Bionic pancreas- in trials- uses insulin and glucagon 3. Continuous Glucose Monitors (CGMs) 1. DEXCOM Share 2. Freestyle libre 19

20 DEXCOM G4 SHARE

Continuous Glucose Monitoring New Technology Systems: DexCom G4-G5 DexCom Share - Freestyle libre- MiniMed / Enlite sensor/hybrid artificial pancreas (courtesy C L Henderson RN, CDE, CPT)

Continuous Glucose Monitoring: 3 day report

23 Questions??